Some Breast Cancer Patients May Not Need Node Dissection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

BERN, Switzerland--A study of 1,619 breast cancer patients has identified a population subset with a very low incidence of lymph node metastases in whom axillary lymph node dissection might be omitted, Andreas Barth, MD, told Oncology News International.

BERN, Switzerland--A study of 1,619 breast cancer patients has identifieda population subset with a very low incidence of lymph node metastasesin whom axillary lymph node dissection might be omitted, Andreas Barth,MD, told Oncology News International.

This series of patients was comprised of those with T1-T4 breast cancerwho underwent level I/II axillary dissection between 1979 and 1995 at TheBreast Center, Van Nuys, Calif. Analysis of 11 clinical/pathological factorsshowed that patients with nonpalpable, non-high grade tumors of less than10 mm, with no lymph-vascular space involvement had an incidence of lymphnode metastases of only 3%.

"In these patients, a lymph node dissection could be omitted, especiallyif they are postmenopausal and ER positive," said Dr. Barth, of theInstitute of Medical Oncology, Bern, Switzerland. Dr. Barth worked on thestudy under Dr. Melvin Silverstein during a fellowship at Van Nuys, andpresented the data at the San Antonio Breast Cancer Symposium.

He pointed out that this population subset comprises only about 7% ofall breast cancer patients, "so it doesn't solve the problem for about93%, and that's where newer techniques, like the sentinel lymph node biopsy,might come in."

Recent Videos
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content